Competitor Analysis: Anaplastic Lymphoma Kinase (ALK) Inhibitors

Publisher: La Merie Publishing
Pages: 17
Format: PDF
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0132
Release Date: August of 2013

150.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Anaplastic Lymphoma Kinase (ALK) Inhibitors

Product description

The present Competitive Intelligence report about Anaplastic Lymphoma Kinase (ALK) Inhibitors provides a competitor evaluation in the field of small molecule and antibody-based inhibitors of Anaplastic Lymphoma Kinase (ALK) for the treatment of solid tumors as of August 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of selective and dual target small molecule Anaplastic Lymphoma Kinase (ALK) inhibitors and of antibody-based ALK inhibitors in oncology. In addition, the report lists company-specific R&D pipelines of ALK inhibitors. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


Competitor Analysis: Anaplastic Lymphoma Kinase (ALK) Inhibitors

Table of Contents

  • Selective, small molecule ALK Inhibitors
  • Dual Target, small molecule ALK Inhibitors
  • Antibody-based ALK Inhibitors
  • Corporate ALK Inhibitor R&D Pipelines

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up